New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 2, 2014
07:38 EDTADXS, PETXAdvaxis files for USDA product license
Advaxis (ADXS) announced that a product license from the USDA has been filed for ADXS-cHER2, its proprietary Her2/neu-directed cancer immunotherapy for the treatment of canine osteosarcoma and other HER2-overexpressing cancers. The filing was submitted by Aratana Therapeutics (PETX), which was granted exclusive worldwide rights by Advaxis to develop and commercialize ADXS-cHER2 in animals. While the USDA has no specific obligation to respond within a prescribed timeframe, the companies expect a response from the USDA to the filing will occur over the next 12 to 18 months.
News For ADXS;PETX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 23, 2014
10:01 EDTADXSOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:06 EDTADXSAdvaxis initiated with a Buy at H.C. Wainwright
Subscribe for More Information
October 20, 2014
07:34 EDTADXSAdvaxis names Mauro Chief Medical Officer
Advaxis (ADXS) announced that it has appointed David Mauro, as executive vice president, Chief Medical Officer Mauro most recently served as executive director, section head oncology clinical development at Merck (MRK). In connection with his appointment, Mauro received a one-time inducement award of 165K restricted shares, of which 55K are fully vested and as of the grant date. The remaining shares vest annually over a two-year period.
October 15, 2014
07:36 EDTADXSAdvaxis provides clinical update for Phase 1/2 trial of ADXS-HPV candidate
Subscribe for More Information
October 13, 2014
08:06 EDTPETXAratana Therapeutics and Atopix complete global licensing agreement
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use